Eyenovia is a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications. Co.'s drug-device therapeutic programs include MicroPine, MicroLine and Mydcombi. MicroPine is Co.'s topical therapy for the treatment of progressive myopia, a back-of-the-eye ocular disease associated with pathologic axial elongation and sclero-retinal stretching. MicroLine is Co.'s investigational pharmacologic treatment for presbyopia. Mydcombi is Co.'s fixed combination formulation of tropicamide-phenylephrine for mydriasis. The EYEN stock yearly return is shown above.
The yearly return on the EYEN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the EYEN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|